Evidence map›Paper›PMID 32656599›Full record

ArticlePathology oncology research : POR2020

The Effect of Methylselenocysteine and Sodium Selenite Treatment on microRNA Expression in Liver Cancer Cell Lines.

Gábor Lendvai, Tímea Szekerczés, Endre Kontsek, Arun Selvam, Attila Szakos, Zsuzsa Schaff, Mikael Björnstedt, András Kiss

Open access · hybridAbstract read
In one paragraph

Article in Pathology oncology research : POR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Selenium-Containing Compounds in Breast Cancer Therapy.Biological trace element research · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Gábor Lendvai2nd Department of Pathology, Semmelweis University, Ulloi 93, Budapest, H-1091, Hungary.ORCID http://orcid.org/0000-0002-0931-380X
Tímea Szekerczés2nd Department of Pathology, Semmelweis University, Ulloi 93, Budapest, H-1091, Hungary.
Endre Kontsek2nd Department of Pathology, Semmelweis University, Ulloi 93, Budapest, H-1091, Hungary.
Arun SelvamDivision of Pathology, F46, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, SE-14186, Stockholm, Sweden.
Attila SzakosDivision of Pathology, F46, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, SE-14186, Stockholm, Sweden.
Zsuzsa Schaff2nd Department of Pathology, Semmelweis University, Ulloi 93, Budapest, H-1091, Hungary.
Mikael BjörnstedtDivision of Pathology, F46, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, SE-14186, Stockholm, Sweden.
András Kiss2nd Department of Pathology, Semmelweis University, Ulloi 93, Budapest, H-1091, Hungary. kiss.andras@med.semmelweis-univ.hu.
Semmelweis University · HUKarolinska University Hospital · SE

Funding

Hungarian Scientific Research Fund NVKP_16_1-2016-0004Hungarian Scientific Research Fund OTKA 128881Semmelweis Egyetem EFOP-3.6.3-VEKOP-16-2017-00009
6 · The paper itself

Abstract

The unique character of selenium compounds, including sodium selenite and Se-methylselenocysteine (MSC), is that they exert cytotoxic effects on neoplastic cells, providing a great potential for treating cancer cells being highly resistant to cytostatic drugs. However, selenium treatment may affect microRNA (miRNA) expression as the pattern of circulating miRNAs changed in a placebo-controlled selenium supplement study. This necessitates exploring possible changes in the expression profiles of miRNAs. For this, miRNAs being critical for liver function were selected and their expression was measured in hepatocellular carcinoma (HLE and HLF) and cholangiocarcinoma cell lines (TFK-1 and HuH-28) using individual TaqMan MicroRNA Assays following selenite or MSC treatments. For establishing tolerable concentrations, IC

Indexed as

Anticarcinogenic AgentsApoptosisBiomarkers, TumorCarcinoma, HepatocellularCell ProliferationGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLiver NeoplasmsMicroRNAsSelenocysteineSodium SeleniteTrace ElementsTumor Cells, CulturedAnticarcinogenic AgentsBiomarkers, TumorMicroRNAsSelenocysteineselenomethylselenocysteineSodium SeleniteTrace ElementsCholangiocarcinomaHepatocellular carcinomaIC50 valueMethylselenocysteinemicroRNA expressionSodium selenite

Identifiers

PMID32656599
PMCPMC7471166
OpenAlexW3041282380

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.